National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 54581 [2016-19417]
Download as PDF
<![CDATA[
54581
Federal Register / Vol. 81, No. 158 / Tuesday, August 16, 2016 / Notices
clearing/approving forms, processing
forms, and acknowledging data entered.
The total estimated annualized
burden hours for all respondents are
1,280. There are no costs to respondents
other than their time. CDC will seek a
three-year approval from OMB.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondents
Initiator/C/I/O
Initiator/C/I/O
Initiator/C/I/O
Initiator/C/I/O
Number of
respondents
Form name
Number of
responses per
CIO
Average
burden per
response
(in hours)
Total burden
(in hours)
.....................................
.....................................
.....................................
.....................................
CDC 0.4601 .....................................
CDC 0.410A .....................................
CDC 0.410B .....................................
Section C of the CDC 0.1475 ..........
64
64
64
64
5
5
5
5
1
1
1
1
320
320
320
320
Totals .........................................
...........................................................
........................
........................
........................
1,280
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2016–19461 Filed 8–15–16; 8:45 am]
Bethesda, MD 20892–9823, (240) 669–5069,
lrust@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: August 10, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2016–19417 Filed 8–15–16; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Implementation Cooperative Agreement
(U01).
Date: September 22, 2016.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Room
3F100, 5601 Fishers Lane, Rockville, MD
20892 (Telephone Conference Call).
Contact Person: Lynn Rust, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room 3G42A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9823,
VerDate Sep<11>2014
18:36 Aug 15, 2016
Jkt 238001
National Institutes of Health
Prospective Grant of Start-Up
Exclusive Evaluation Option License
Agreement: Small Molecule
Therapeutic Compounds
Encompassed Within the Licensed
Patent Rights for the Treatment of
Thioesterase Deficiency Disorder
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
This notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of a
Start-Up Exclusive Evaluation Option
License Agreement to practice the
inventions embodied in the following
Patent Applications to Circumvent
Pharmaceuticals Inc. (‘‘Circumvent’’)
located in Pasadena, California, USA:
SUMMARY:
Intellectual Property
United States Provisional Patent
Application No. 61/473,692, filed April
8, 2011, titled ‘‘Small molecule
therapeutic compounds targeting
thioesterase deficiency disorders and
methods of using the same’’ [HHS
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
Reference No. E–157–2011/0–US–01],
status: Expired;
International Patent Application No.
PCT/US2012/32772 filed April 9, 2012
titled ‘‘Small molecule therapeutic
compounds targeting thioesterase
deficiency disorders and methods of
using the same’’ [HHS Reference No. E–
157–2011/0–PCT–02], status: Converted;
European Patent Application No.
12716889.6, filed November 7, 2013,
titled ‘‘Small molecule therapeutic
compounds targeting thioesterase
deficiency disorders and methods of
using the same’’ [HHS Reference No. E–
157–2011/0–EP–03], status: Pending;
and
United States Patent Application No.
14/110,393, filed October 7, 2013, titled
‘‘Small molecule therapeutic
compounds targeting thioesterase
deficiency disorders and methods of
using the same’’ [HHS Reference No. E–
157–2011/0–US–04], status: Pending.
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The territory of the prospective StartUp Exclusive Evaluation Option License
Agreement may be worldwide and the
field of use may be limited to: ‘‘Small
molecule therapeutic compounds
encompassed within the Licensed
Patent Rights for the treatment of
thioesterase deficiency disorders’’
Upon the expiration or termination of
the Start-up Exclusive Evaluation
Option License Agreement, Circumvent
will have the exclusive right to execute
a Start-Up Exclusive Patent License
Agreement which will supersede and
replace the Start-up Exclusive
Evaluation Option License Agreement,
with no greater field of use and territory
than granted in the Start-up Exclusive
Evaluation Option License Agreement.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
E:\FR\FM\16AUN1.SGM
16AUN1
]]>Agencies
[Federal Register Volume 81, Number 158 (Tuesday, August 16, 2016)]
[Notices]
[Page 54581]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-19417]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Clinical Trial Implementation
Cooperative Agreement (U01).
Date: September 22, 2016.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Room 3F100, 5601 Fishers
Lane, Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Lynn Rust, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities, Room
3G42A, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC
9823, Bethesda, MD 20892-9823, (240) 669-5069, lrust@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: August 10, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-19417 Filed 8-15-16; 8:45 am]
BILLING CODE 4140-01-P
